Related Experiment Video
Updated: Nov 6, 2025
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively
Maël Heiblig1,2, Nicolas Duployez3, Alice Marceau3
1Hospices Civils de Lyon, Hematology Department, Lyon-Sud Hospital, 69310 Pierre Bénite, France.
Abstract:
Minimal residual disease (MRD) is now a powerful surrogate marker to assess the response to chemotherapy in acute myeloid leukemia (AML). DNMT3A mutation has been associated with adverse outcomes. In this study, we aimed to investigate the impact of DNMT3A status on NPM1 MRD predictive value for survival in a retrospective cohort of AML patients aged over 60 years old treated intensively. A total of 138 patients treated for NPM1-mutated AML in two French institutions were analyzed retrospectively. DNMT3A status did not influence the probability of having a ≥ 4log MRD1 reduction after induction. Only 20.4% of FLT3-ITD patients reached ≥ 4log MRD1 reduction compared to 47.5% in FLT3wt cases. A 4log reduction of NPM1 MRD was associated with a better outcome, even in FLT3-ITD mutated patients, independent of the allelic ratio. DNMT3A negative patients who reached a 4log reduction had a superior outcome to those who did not (HR = 0.23; p < 0.001). However, postinduction NPM1 MRD1 reduction was not predictive of OS and LFS in DNMT3Amut patients. These results confirm that post-induction NPM1 MRD1 is a reliable tool to assess disease outcome in elderly AML patients. However, the presence of DNMT3A also identifies a subgroup of patients at high risk of relapse.
Insights
Minimal residual disease (MRD) monitoring in acute myeloid leukemia (AML) is crucial. While NPM1 MRD predicts survival in elderly AML patients, DNMT3A mutations identify a high-risk subgroup needing closer monitoring for relapse.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Minimal residual disease (MRD) is a key prognostic marker in acute myeloid leukemia (AML).
- DNMT3A mutations are linked to poorer outcomes in AML.
- NPM1 MRD is a valuable tool for assessing treatment response.
Purpose of the Study:
- To evaluate the impact of DNMT3A mutation status on the predictive value of NPM1 MRD for survival in elderly AML patients.
- To analyze the interplay between DNMT3A, NPM1 MRD, and FLT3-ITD in AML prognosis.
Main Methods:
- Retrospective analysis of 138 elderly AML patients with NPM1 mutations treated intensively.
- Assessment of DNMT3A and FLT3-ITD mutational status.
- Evaluation of post-induction NPM1 MRD levels (MRD1) and their correlation with overall survival (OS) and leukemia-free survival (LFS).
Main Results:
- DNMT3A status did not affect the achievement of a 4-log MRD1 reduction.
- FLT3-ITD mutations were associated with lower rates of 4-log MRD1 reduction compared to FLT3 wild-type.
- A 4-log NPM1 MRD reduction predicted better outcomes, irrespective of FLT3-ITD status.
- DNMT3A-negative patients achieving a 4-log reduction showed superior outcomes.
- NPM1 MRD1 reduction was not predictive of OS and LFS in DNMT3A-mutated patients.
Conclusions:
- Post-induction NPM1 MRD1 is a reliable prognostic tool for elderly AML patients.
- DNMT3A mutations identify a subgroup of elderly AML patients at high risk of relapse.
- NPM1 MRD monitoring remains valuable, but DNMT3A status refines risk stratification in AML.
